St. Jude Medical Inc.
) announced results from a large-scale clinical study revealing
that its Quartet left-ventricular (LV) quadripolar lead offers more
effective management of common pacing complications compared to
systems with bipolar leads, thus enabling better management of
heart failure patients.
The MORE-CRT data - More Options available with a quadripolar LV
lead pRovidE in clinic solutions to CRT challenges, was presented
at the European Society of Cardiology Congress (ESC) 2014. Results
disclosed that complications occurred less frequently and were
managed more efficiently in patients who received the Quartet lead
than in patients who received bipolar electrode leads.
The MORE-CRT study involved a randomized clinical trial of over
1,000 patients. More than 60 centers from 13 countries participated
in the study. The primary endpoint of the clinical study was
freedom from intra- and post-operative LV lead-related events at
The study, involving a comparison of the St. Jude Medical Quartet
lead with bipolar LV leads, further demonstrated that patients
implanted with a Quartet lead showed a 40% lower risk of combined
LV lead-related events relative to patients implanted with a
bipolar LV lead.
Quadripolar technology aims at revolutionizing Cardiac
Resynchronization Therapy (CRT) pacing options in order to
facilitate better management of heart failure patients. It enables
LV pacing at the preferred site without compromising on lead
Further, the technology can lead to greater CRT implant efficiency,
better post-operative efficiency and opportunities to improve CRT
The quadripolar pacing technology is specifically more advanced as
the failed implant rate in heart failure patients receiving a CRT
system with bipolar LV pacing leads is significantly high and may
result in complications like anatomy (creating lead stability
problems), phrenic nerve stimulation (PNS) or poor electrical
Data from the MORE-CRT study adds to the growing body of clinical
evidence for the St. Jude Medical Quadripolar Lead system and will
play a vital role in treatment decision making going forward.
Additional Clinical Evidence
Also presented at the ESC 2014 were 12 month results from the St.
Jude Medical MultiPoint Pacing clinical study. Twelve month
results, consistent with the three month data, indicated a 19%
increase in the number of patients responding to CRT compared to
the standard-of-care, biventricular pacing.
Data presented at the 2014 Heart Rhythm Society's (HRS) Annual
Scientific Sessions in May, demonstrated an 18% reduction in
mortality as well as other improved clinical outcomes and better
cost utilization with St. Jude Medical's quadripolar technology.
The company also presented additional data at HRS 2014, revealing
that the use of its Quartet Quadripolar LV lead lowered
hospitalization cases by 53% compared to patients in the
non-quadripolar group. The lower hospitalization rate translated
into a statistically significant 62% reduction in overall costs for
both health care systems and patients.
The large and growing body of clinical evidence combined with a
strong product pipeline, including next-generation MultiPoint
pacing (investigational device in the U.S.), makes St. Jude
Medical's quadripolar system the standard of care in improving the
management of CRT.
Currently, St. Jude Medical carries a Zacks Rank #3 (Hold). Some
better-ranked stocks in the medical products industry include ICU
Medical, Inc. (
), Abaxis, Inc. (
) andNeogen Corp. (
). ICU Medical sports a Zacks Rank #1 (Strong Buy), while both
Abaxis and Neogen carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ST JUDE MEDICAL (STJ): Free Stock Analysis
ABAXIS INC (ABAX): Free Stock Analysis Report
ICU MEDICAL INC (ICUI): Free Stock Analysis
NEOGEN CORP (NEOG): Free Stock Analysis Report
To read this article on Zacks.com click here.